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Dosimetry of 103-Pd Eye Plaque
Brachytherapy
Pooneh Saidi and Mahdi Sadeghi
Abstract
In this study, the dose distribution has been calculated for the Collaborative
Ocular Melanoma Study (COMS) eye plaques at various diameters 10–22 mm,
loaded with the 103-Pd brachytherapy seeds (Model IR06-103Pd). Several Monte
Carlo (MC) simulations have been employed to carry out the gold backing and
Silastic insert effect on dose distribution around the eye plaque. Version 5 of the
Monte Carlo N-particle (MCNP) code has been used to carry out the simulations.
The new palladium seed was modelled in three geometric orientations (ideal,
vertical and diagonal). Results are compared with the calculated data for COMS
eye plaque loaded with Theragenics model 200 and Best model 2335 palladium-103
seeds and model 6711 iodine-125 seeds. The calculated dose rate constant of the
IR06-103Pd seed was found to be 0.692  0.020 cGy h1 U1. The air kerma
strength to deliver 85 Gy to tumour apex in a water medium was found to be
4.10 U/seed. The dosimetric parameters calculated in this work for the new
palladium seed indicate the IR06-103Pd seed is suitable for use in brachytherapy.
In COMS plaques, the dose distribution to points of interest was compared for three
103-Pd seed models. With the exception of sclera dose and for a given prescription
dose, the IR06 seed delivers lower dose ocular points of interest.
Keywords: eye plaque, palladium-103, brachytherapy, dosimetry
1. Introduction
The most common primary intraocular malignancy in adults is choroidal
melanoma, accounting for 5% of all melanomas, originating within the pigmented
cells of the choroid. More common in Caucasians, the Collaborative Ocular
Melanoma Study (COMS) found the mean age at diagnosis to be 60 years.
Generally, they are located posterior to the ciliary body and often found during
ophthalmic examination [1, 2].
The plaque is temporarily sutured to the sclera overlying the tumour, left in
place for 5–7 days and then surgically removed. Temporary placement of an
episcleral plaque containing radioactive material has gained acceptance as a treat-
ment for choroidal melanoma. Compared to enucleation, eye plaque brachytherapy
provides better outcomes for uveal melanoma [3]. The choice of the treatment
1
method is depending on the size and location of the tumour [4, 5]. One of the most
common primary intraocular malignancies is the choroidal. Patients with a
medium-sized choroidal melanoma (between 2.5 and 10 mm in height and <16 mm
basal diameter) are candidates for episcleral plaques [6]. It offers good chances of
conserving the eye, often with at least some useful vision [7, 8]. Compared to
charged particle radiation, the collimating effects of an eye plaque provides better
conformality than possible with protons and essentially zero dose to the brain and
orbit behind the plaque. Different types of eye plaque are used for the treatment of
intraocular tumours, which are most often round, made of gold, silver, or stainless
steel and come in several diameters depending on the tumour size. The Collabora-
tive Ocular Melanoma Study group provided the first standardized methods for
administering ocular brachytherapy treatments for uveal melanoma in 1985, by
the eye plaques, and for the brachytherapy seeds, the dose was calculated using a
point source approximation, and no corrections were made for source anisotropy,
the plaque or insert materials of the plaques and also photon backscatter or
fluorescence photons from the plaque backing. In the early 1990s, the begging of
the investigation of the effect of the plaque backing and material insert (such as
Silastic) on dose distribution and the recommended dosimetry protocol for eye
plaques was issued by the Task Group (TG) 129 report. This report includes the
correction factors/formula for heterogeneous plaque materials (backing and insert
material) [9–12]. Common isotopes used in ocular brachytherapy are 125I, 103-Pd
and 106-Ru. Iodine125 is currently the most commonly used and well
documented in the literature. Some few centers use palladium-103, observing that
the low gamma emission of 103-Pd, 20 keV, presents less radiation exposure hazard
to personnel [13]. But due to the low energy of the photons from 103-Pd, the effect
of backscatter from plaque backing on dose distribution is expected to be signifi-
cant. Many reports are available concerning the effect of the gold plaque backing
on dose rate [14, 15]. They reported a dose enhancement near the seed due to the
backscatter photons from the gold backing. Chiu-Tsao et al. [16], Thomson et al.
[17] and de la Zerda et al. [12] reported that dose at small distances from the seed
was reduced due to the presence of gold backing. In this work, the Monte Carlo
technique is used to study dose rate distributions around the COMS gold eye
plaques having diameters from 10 to 22 mm and fully loaded with a palladium
seed. The seeds were distributed into Silastic insert inside the 10–22 mm diameter
COMS eye plaques. As reported by the American Association of Physicists in
Medicine (AAPM), TG-43U1 recommendations, before using each new source, the
dosimetric characteristics of the source need to be determined to provide reliable
data for use in treatment planning calculations [18]. As stated by TG-43U1
guidelines, we have calculated the dosimetric parameters of the IR06-103Pd source.
As the internal components of the seed are free to move within the titanium
capsule, their location can vary with seed orientations. In our Monte Carlo
calculations, three geometric models of the seed (ideal, vertical and diagonal) were
also developed. Since the tumour control rate for plaque brachytherapy is high, the
most important issue is the side effects in healthy structures (points of interest)
in the eye region. Doses at points of interest were calculated for selected plaque
positions on the surface of an eye. Further Monte Carlo simulations have been
employed to investigate the effect of plaque gold backing and Silastic inserts on
dose distributions along the central axis of the eye plaque and at critical points in
the eye region. To investigate the effect of the plaque backing and Silastic insert
on dose distributions, four different configurations of plaque were simulated for
the IR06-palladium seed model, namely:
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1. Silastic insert with gold backing
2. Silastic insert with water replacing gold backing
3. Liquid water replacing Silastic, with gold
4.Liquid water replacing Silastic and gold (seeds alone in water)
Finally, dose along the plaque’s central axis and at the critical points are com-
pared with 125-I (6711 model) and 103-Pd (Theragenics model 200) seeds loaded in
COMS eye plaque [17].
2. Materials and methods
In this work, the Monte Carlo calculations have been performed to calculate the
dose distribution around the eye plaque. The Monte Carlo method is a numerical
technique using random numbers and probability to solve problems. It performs an
effort to model nature through direct simulation for any possible results, by a
probability distribution, for any cause that has inherent uncertainty. The name of
this method comes from the casino name in Monaco, because of roulette, a simple
random number generator. Clinical dose calculations are generally carried out with
the patient treated as water equivalent and a dose of 85 Gy prescribed to the tumour
apex. In the calculation the effects from the presence of the plaque backing, insert
and intraocular media are considered [19]. In this work, the dose distributions were
simulated using the MCNP5 Monte Carlo (MC) radiation transport code published
by the Los Alamos National Laboratory, and the MCPLIB04 photon cross-section
library is based on the ENDF/B-VI data [20]. The 103-Pd photon spectrum used in
these simulations was obtained from TG-43U1 table XIII [18]. To calculate absorbed
dose and kerma, the particle fluence and cell-heating tallies, F4 and F6, have been
used, respectively.
2.1 103-Pd source description
The source used in this study is the palladium-103 source model IR06-103Pd seed
which is designed and fabricated in Agricultural, Medical and Industrial Research
School (AMIRS). The production of 103-Pd is carried out via the 103Rh(p,n)103Pd
reaction which is well suited to low-energy cyclotrons. 103-Rh target was irradiated
via cyclotron (IBA-Cyclone30, Belgium) at the AMIRS. The solid targetry system in
this cyclotron is made up of a pure copper backing on which the target materials are
electrodeposited. The target that undergoes bombardments by the proton beam at
the cyclotron production consists of three layers as follows: (I) rhodium layer, (II)
copper layer and (III) copper layer without induced proton beam [21]. All irradia-
tion of the electroplated Rh targets were performed at 200 μA beam current. The
rhodium targets were prepared by the electrodeposition technique. Thus, the elec-
trodeposition experiments were performed in acidic sulphate media using
RhCl3.3H2O, Rh2(SO4)3. The radiochemical processing of the irradiation targets
involved (a) dissolution, (b) radiochemical separation of 103-Pd from the Rh target
solution and (c) recovery of 103-Pd as the final product from the organic phases
[22]. After the chemical separation process, 103-Pd radioactive material is absorbed
uniformly in the resin Amberlite IR-93 resin (20–50 mesh) bead to encapsulate
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inside the titanium capsule. The seed contains five resin beads, each in diameter of
0.6 mm with the compositions of (by weight percent) C, 90%; H, 8%; Pd, 1%; Cl,
0.7%; and N, 0.3%, with the density equal to 1.14 g/cm3. The resin beads are packed
inside a titanium capsule of 4.7 mm length; 0.7 and 0.8 mm internal and external
diameters, respectively; and 0.6 mm thick end caps and with an effective length of
3 mm. 103-Pd radioactive material is absorbed uniformly in the resin bead volume
[23]. Figure 1 shows a schematic diagram of the IR06-103Pd seed. As the resin beads
are free to move within the titanium capsule, their location can vary with seed
orientations. Following the TG-43U1 recommendation for “good practice for Monte
Carlo calculations” [18], mechanical mobility of the internal component of the seed
has been considered in the simulations, and three geometric models (ideal, vertical
and diagonal) of the seed were developed as shown in Figure 1a–c.
2.2 Seed Monte Carlo dosimetry
The IR06-103Pd brachytherapy seed has been simulated in the center of a
spherical water phantom in 15 cm radius with an array of 1 mm thick detector rings.
Detectors were defined at distances of r = 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 7 cm, away
from the palladium-103 seed and at polar angles relative to the seed longitudinal axis
from 0 to 90°. The rings were also bounded with two cones (10°) bisecting the
phantom sphere corresponding to points in two-dimensional TG-43U1 dose formal-
ism for ideal orientation and from 0 to 180° for vertical and diagonal orientations,
with 10° increment. A cross section of the detector arrangement is shown in Figure 2.
To calculate the dosimetric parameters of the seed, TG43-U1 formalism has been
used, which are briefly described by Sadeghi et al. [24].
According to TG43-U1 recommendation, the proposed formula for
two-dimensional dose rate is
_D r; θð Þ ¼ SKΛ
G r; θð Þ
G r0; θ0ð Þ
g rð ÞF r; θð Þ (1)
Figure 1.
Schematic diagram of the IR06-103Pd seed in (a) ideal, (b) diagonal and (c) vertical orientation.
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where:
_D r; θð Þ is the dose rate in the water at the distance r in cm from the source.
θ is the polar angle specifying the point of interest.
SK is the air kerma strength and the unit is U ¼ cGy cm2h
1.
Λ is the dose rate constant with the unit of cGy h1U1.
G r;θð Þ
G r0;θ0ð Þ
is the geometry factor; r0 ¼ 1 cm and θ0 ¼ 90
0 (reference position).
g rð Þ andF r; θð Þ are the radial dose function and the anisotropy function, respectively.
The dose rate constant, Λ, for the seed was calculated as the ratio of the dose to
water at 1 cm from the seed along the transverse axis to the source’s air kerma
strength, SK, at distance r from the source center. The air kerma strength was
calculated using the following equation [18]:
SK ¼ _K δ rð Þr
2 (2)
As the energy of the photons from 103-Pd are low, in the Monte Carlo calcula-
tions, all the generated electrons from the photon collisions are absorbed locally, so
it was expected that dose is equal to kerma at all points of interest. The air kerma
rate, _K δ rð Þ, of the seed was determined by calculating the dose in 1 mm thick air-
filled rings in a vacuum. The rings were bounded by 86 and 94° conics and defined
with a radial increment of 5–150 cm along the transverse axis of the source to find
the SK that is independent to distance [14]. The dose distributions were calculated
from the energy deposition averaged over a cell tally F6 in MeV/g/source photon.
For the calculations, the titanium characteristic X-ray production was suppressed
with δ = 5 keV (δ is the energy cut-off) [25]. The radial dose function expresses the
effect of tissue attenuation on photons emitted from seed and defines the dose fall-
off along the seed transverse axis due to the attenuation and scattering of the
photon. g(r) was calculated by the following equation:
gX rð Þ ¼
_D r; θ0ð Þ
_D r0; θ0ð Þ
GL r0; θ0ð Þ
GL r; θ0ð Þ
(3)
Dose variations, as the distribution of seed radioactivity, oblique filtration, and
self-absorption in the encapsulating material, are defined by the 2D anisotropy
function as follows:
Figure 2.
Cross section of the detector arrangement for Monte Carlo calculations.
5
Modelling, Simulation and Dosimetry of 103-Pd Eye Plaque Brachytherapy
DOI: http://dx.doi.org/10.5772/intechopen.88144
F r; θð Þ ¼
_D r; θð Þ
_D r; θ0ð Þ
GL r; θ0ð Þ
GL r; θð Þ
(4)
The simulations were performed in water with 1 109 histories giving statistical
uncertainties of 2.5 and 3.5% at 1 and 5 cm along the long axis and 0.05–0.1% at 1
and 5 cm on the transverse plane. The statistical uncertainty in the air was 1% with
7  107 histories. In this study, the Monte Carlo simulation was benchmarked with
the brachytherapy seed model Theragenics 200 [18, 26].
2.3 Eye plaque simulation
To determine the dose rate around the eye plaque, eyeball and eye plaque,
which are loaded with the seeds, are modelled in the center of 20  20  15 cm3
water phantom. The seeds were distributed in the Silastic insert. The longitudinal
axes of the seeds are perpendicular to the eye phantom central plane.
The total dose is calculated by the following equation [14]:
_d x; y; zð Þ ¼ SP







where _d x; y; zð Þ is the dose rate at (x, y, z) position, Sk is the air kerma strength
per history calculated by using Monte Carlo methods, A is the activity (mCi), K is
the photons emitted per unit activity (photons mCi1) and n is the number of seeds
which are loaded in the eye plaque. The COMS eye plaques which are used in this
study are composed of two parts with diameters ranging from 10 to 22 mm in 2 mm
increments:
a. The gold backing, with the composition of (by weight) 77% gold, 14% silver,
8% 159 copper and 1% palladium and a density of 15.8 g/cm3 [27]
b.The Silastic insert as a seed career with the composition of (by weight) 6.3%
hydrogen, 24.9% carbon, 28.9% oxygen, 39.9% silicon and 0.005% platinum
and a density of 1.12 g/cm3 [15]
The plaque assumed a standard eye diameter of 24.6 mm by considering lens and
homogenized eye materials according to ICRU 46 [28]. The position of the points is
followed by Thomson et al. [17] (Figure 3). The lens is modelled in the homogenized
eye, and to obtain the dose rate, the plaque and eye ball are then modelled at the
center of the spherical water phantom with 30 cm diameter. The plaque backing
and Silastic insert effect on dose rate is obtained by replacing water with gold and
Silastic insert. Central axis depth dose to water was determined using the F6 tally of
MCNP for 0.05 mm radius and 0.01 mm thick cylindrical voxels from the outer
sclera (1 mm) to 11 mm inside the eye in 0.5 mm steps [2]. For the comparison
doses to interest points (center of the eye, macula, optic disk, proximal sclera,
tumour apex, lacrimal gland and retina opposite the apex) have been determined.
The total dose is calculated following Melhus and Rivard [14] and Thomson et al.
[17] verbatim: “The Monte Carlo simulations provide the dose in a voxel per
history. The dose rate is calculated by dividing this number by the air kerma
strength per history for the relevant seed type and multiplying by the number of seeds
and the air kerma strength per seed. The air kerma strength per seed is chosen in
order to obtain a prescription dose of 85Gy at the tumour apex (5 mm on the central
axis) in 168 hours for 103-Pd. The total dose delivered during treatment is then
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determined by integrating over the treatment time, taking into account the expo-
nential decay of the source”. Also, the photoelectric absorption, fluorescent emission
and Rayleigh and Compton scattering, of characteristic K- and L-shell X-rays, are
all simulated. For variance reduction, the electron and photon transport energy cut-
off in all calculations was selected at 1 and 5 keV, respectively [29]. In the simula-
tion 3.8  108 photon histories were simulated, and the statistical uncertainties at 5
and 11 mm (tumour apex) depth of central axis were obtained at 0.7 and 1.1%,
respectively. Statistical uncertainties at the opposite side of the eye exceeded 4%
which has the greatest uncertainty among the points on interest.
3. Results and discussions
3.1 Seed dosimetry benchmarking
In this work, the Monte Carlo simulation was benchmarked with the
Theragenics model 200 source. The comparison between the calculated value of Λ
for the model 200 in this study, 0.685 cGy h1 U1, and the previously published
data for the seed [18], 0.686 cGy h1 U1 (0.1% difference), shows the accuracy
of our simulation method. The result has been presented in Table 1. Based on the
calculations, the dose rate constant for the IR06-103Pd source in ideal orientation is
estimated to be 0.692  0.020 cGyh1U1 which is comparable with the other two
commercial sources. Calculated SK per contained activity for model 200 in this work
was 0.722 U mCi1. The result was compared to 0.721 U mCi1 for Williamson’s
WAFAC simulation, [26] and Melhus et al. [14] calculations. The values of Λ in
three seed orientations ranged from 0.689 to 0.697 cGy h1 U1, with a 0.34%
Figure 3.
Points of interest for eye plaque dosimetry, given in the center of eye reference frame (scale in centimeters) for a
right eye [17]. In the figure a plaque midway between the posterior pole and equator temporal is shown. All
points of interest are indicated (with the exception of the lacrimal gland, which does not lie in the plane shown).
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uncertainty. According to TG-43U1, a standard uncertainty of 3% is acceptable for
Monte Carlo studies. The dose rate constant can be calculated by normalizing to the
SK of the vertical orientation and the source geometry during the NIST calibration.
The values, in this case, are 0.680 0.020 cGy h1 U1,1.7% lower than the value
in the ideal orientation. This result obtained in this study is comparable with Λ
values obtained for other 103-Pd sources which are presented in TG-43U1 report.
Table 1 shows the calculated dose rate constant for the IR06-103Pd seed and the
measured and calculated values of Λ, for NASI model MED3633, Theragenics model
200 and Best model sources.
The calculated line radial dose function gL(r), of the IR06-
103Pd for ideal orien-
tation, was fit to a fifth-order polynomial function yielding the following
relationship:






a0 = 1.785, a1 = 1.064, a2 = 3.385  10
–1, a3 = 7.062  10
–2, a4 = 8.469  10
–3
and a5 = 4.173  10
–4 define R2 = 9.999  101.
Figure 4 presents the radial dose function, g(r), for IR06-103Pd seed and three
other commercial sources. Table 2 shows the differences between the results of
this study and AAPM TG-43U1 reference data for model 200. As the differences are
<3%, the agreement between these data sets is acceptable. The radial dose function
values for two other geometric models, vertical and diagonal, were also calculated,
and the disagreement between them varied from <2%. The anisotropy function, F
(r,θ), of the IR06-103Pd seed was calculated in the phantom of water, at radial
distances of r = 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5 and 7 cm relative to the seed center
and polar angle, θ, ranging from 0 to 180° for vertical and diagonal orientations and
0–90° for ideal orientation, in 10° increment with respect to the seed long axis. The
results are shown in Table 3.
Source type Method Medium Λ (cGy h1 U1)
IR06-103Pd Monte Carlo simulation (ideal)a Liquid water 0.692  0.021
Monte Carlo simulation (diagonal)a Liquid water 0.697  0.021
Monte Carlo simulation (vertical)a Liquid water 0.689  0.021
MED3633 TLD dosimetryb Solid water 0.688  0.05
Monte Carlo simulationc Liquid water 0.677  0.02
Theragenics model 200 TLD dosimetryd Solid water 0.650  0.08
Monte Carlo simulatione Liquid water 0.686  0.03
Monte Carlo simulationa Liquid water 0.685  0.02
Best model 2335 TLD dosimetryf Solid water 0.69  0.08








Monte Carlo calculated dose rate constant, Λ, of the IR06-103Pd and model 200 seeds in comparison with the
measured and calculated values of model MED3633, model 200 and model 2335 seeds.
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Figure 5 shows a comparison between the calculated anisotropy function of the
IR06-103Pd seeds at a distance of 2 cm from the source center in water with the
other published data (in ideal orientation). The values of the anisotropy function for
the new 103-Pd sources agreed with those for the model MED3633, Theragenics
model 200 and Best® double-wall 103-Pd sources [18, 26, 30] are found in 4% in
angles >20°. Due to the thick end caps of the IR06-103Pd source, the differences in
smaller angles can be as large as up to 17%.
3.2 Plaque Monte Carlo simulations
Table 4 shows the calculated central depth dose distribution for COMS eye
plaques loaded with IR06-103Pd seeds in the Silastic insert.
Figure 4.
Comparison of the calculated radial dose function of IR06-103Pd seeds in water versus other available
sources [18, 30].
r (cm) gL(r)
Theragenics 200 Percent difference (%) IR06-103Pd
Ref. [26] Present work
0.5 1.300 1.330 2 1.333
0.75 1.150 1.170 2 1.144
1 1.000 1.000 0 1.000
1.5 0.749 0.755 1 0.756
2 0.555 0.567 2 0.566
3 0.302 0.305 1 0.318
4 0.163 0.168 3 0.168
5 0.089 0.091 3 0.091
7 0.026 0.027 2 0.026
Table 2.
Monte Carlo calculations for radial dose function, gL(r), for IR06-
103Pd and model 200 seeds compared to
reference Monte Carlo data.
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The depth dose distribution has been calculated in 0.5 mm steps between the
outer sclera (1 mm) to 3 mm and in 1 mm steps from 4 to 10 mm. The dose
distribution is also calculated in water medium to obtain the effect of the Silastic
insert and the plaque backing on central axis dose distribution. In this study, the
a. 2-D anisotropy function, F(r,θ), in ideal seed orientation
r (cm) Θ=
0° 10° 20° 30° 40° 50° 60° 70° 80° 90°
0.25 0.053 0.074 0.616 0.854 0.924 0.959 0.979 0.992 0.998 1.000
0.5 0.132 0.165 0.472 0.701 0.845 0.927 0.964 0.985 0.996 1.000
0.75 0.169 0.211 0.480 0.686 0.823 0.912 0.960 0.985 0.997 1.000
1 0.190 0.242 0.491 0.686 0.816 0.903 0.956 0.982 0.996 1.000
1.5 0.229 0.281 0.512 0.692 0.813 0.899 0.952 0.982 0.995 1.000
2 0.265 0.309 0.526 0.696 0.814 0.896 0.950 0.982 0.996 1.000
3 0.294 0.345 0.545 0.705 0.815 0.897 0.949 0.981 0.997 1.000
4 0.319 0.369 0.558 0.709 0.818 0.895 0.948 0.979 0.995 1.000
5 0.337 0.392 0.568 0.715 0.820 0.900 0.948 0.981 0.995 1.000
7 0.405 0.428 0.601 0.730 0.831 0.900 0.948 0.982 1.004 1.000
b. 2-D anisotropy function, F(r,θ), in vertical seed orientation
r (cm) Θ=
0° 10° 20° 30° 40° 50° 60° 70° 80° 90°
0.25 1.155 0.471 0.526 0.591 0.568 0.504 0.426 0.351 0.308 1.000
0.5 0.958 0.436 0.485 0.597 0.650 0.672 0.682 0.695 0.720 1.000
0.75 0.931 0.453 0.508 0.631 0.702 0.743 0.775 0.806 0.840 1.000
1 0.907 0.471 0.531 0.656 0.733 0.784 0.823 0.856 0.895 1.000
1.5 0.900 0.497 0.560 0.685 0.767 0.824 0.868 0.905 0.945 1.000
2 0.880 0.514 0.579 0.704 0.786 0.845 0.888 0.928 0.967 1.000
3 0.859 0.541 0.606 0.724 0.810 0.867 0.912 0.952 0.992 1.000
4 0.851 0.557 0.623 0.737 0.817 0.875 0.924 0.961 1.004 1.000
5 0.810 0.577 0.637 0.747 0.826 0.883 0.927 0.968 1.009 1.000
7 0.889 0.610 0.668 0.769 0.846 0.901 0.946 0.977 1.024 1.000
r (cm) 100° 110° 120° 130° 140° 150° 160° 170° 180°
0.25 0.945 0.682 0.877 0.942 0.975 0.993 1.003 1.005 1.002
0.5 0.918 0.652 0.741 0.855 0.933 0.974 0.994 1.003 1.002
0.75 0.887 0.661 0.739 0.837 0.916 0.964 0.989 1.000 1.001
1 0.874 0.673 0.743 0.835 0.908 0.960 0.988 1.000 1.001
1.5 0.856 0.685 0.753 0.837 0.906 0.956 0.985 0.999 1.001
2 0.851 0.696 0.758 0.840 0.905 0.954 0.984 0.998 1.001
3 0.845 0.712 0.768 0.845 0.907 0.954 0.984 0.998 1.001
4 0.842 0.722 0.778 0.848 0.907 0.953 0.983 0.997 1.000
5 0.839 0.733 0.785 0.853 0.909 0.953 0.983 0.996 1.000
7 0.852 0.757 0.805 0.869 0.919 0.963 0.988 1.003 1.004
10
Theory, Application, and Implementation of Monte Carlo Method in Science and Technology
required air kerma strength per seed (SK) is calculated to deliver prescription dose
(85 Gy) to the apex of the tumour (5 mm depth) for 168 hours of implant. In
addition, to investigate the effect of different materials constituting the COMS
plaque on dose distributions near the plaque, the ratio of dose in three media
(discussed above) relative to dose in water medium is shown in Figure 6.
3.3 Effect of the gold backing
The effect of 20 mm gold plaque backing on dose distribution along the central
axis is shown in Figure 7, which provides central axis depth dose curve for full
loaded IR06-103Pd, Theragenics 200 and model 2335 seeds with water replacing the
Silastic. This figure demonstrates dose is increased near the plaque; now this well-
known effect is due to L-shell fluorescence photons emitted by atoms in the plaque
backing [27]. Emission photons from palladium seeds with an average energy of
about 21 keV excite the L-shell in gold and silver [31] which are the composition of
the plaque backing. The excitation of these shells results in the emission of fluores-
cence photons, so this event explains why dose increases near the plaque. About
c. 2-D anisotropy function, F(r,θ), in diagonal seed orientation
r (cm) Θ=
0° 10° 20° 30° 40° 50° 60° 70° 80° 90°
0.25 1.155 0.471 0.525 0.591 0.567 0.502 0.424 0.352 0.310 1.000
0.5 0.969 0.438 0.485 0.597 0.651 0.673 0.682 0.696 0.723 1.000
0.75 0.941 0.453 0.508 0.631 0.701 0.744 0.775 0.805 0.842 1.000
1 0.918 0.471 0.530 0.657 0.734 0.783 0.822 0.857 0.897 1.000
1.5 0.907 0.497 0.560 0.686 0.767 0.824 0.866 0.906 0.947 1.000
2 0.881 0.515 0.579 0.704 0.786 0.845 0.889 0.930 0.972 1.000
3 0.857 0.540 0.607 0.724 0.806 0.865 0.910 0.953 0.995 1.000
4 0.852 0.556 0.623 0.738 0.817 0.873 0.921 0.962 1.003 1.000
5 0.810 0.577 0.637 0.746 0.825 0.883 0.928 0.969 1.012 1.000
7 0.888 0.610 0.669 0.769 0.846 0.902 0.946 0.979 1.027 1.000
r (cm) 100° 110° 120° 130° 140° 150° 160° 170° 180°
0.25 0.945 0.684 0.879 0.943 0.974 0.993 1.002 1.003 1.004
0.5 0.921 0.652 0.741 0.856 0.935 0.975 0.994 1.002 1.003
0.75 0.889 0.663 0.739 0.837 0.915 0.964 0.989 1.001 1.002
1 0.876 0.673 0.744 0.836 0.910 0.961 0.989 1.000 1.002
1.5 0.860 0.686 0.752 0.837 0.905 0.956 0.985 0.999 1.001
2 0.852 0.697 0.758 0.841 0.905 0.955 0.984 0.999 1.001
3 0.847 0.713 0.769 0.845 0.906 0.954 0.984 0.998 1.002
4 0.843 0.723 0.778 0.848 0.907 0.954 0.983 0.997 1.001
5 0.842 0.733 0.785 0.853 0.908 0.953 0.983 0.996 1.000
7 0.856 0.759 0.806 0.868 0.919 0.963 0.988 1.003 1.005
Table 3.
2-D anisotropy functions for the IR06-103Pd seed calculated by Monte Carlo method for the (a) ideal
orientation, (b) vertical orientation and (c) diagonal orientation.
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0.7% dose enhancement is observed near the plaque which is loaded with
IR06-103Pd seeds, but as the fluorescence photons are absorbed (mean free path is
about 2 mm), after a few millimeters, the dose decreases in the order of 6.5%. In
Thomson et al. [17] work, a dose decrease of about 6–6.3% at the opposite side of
the eye for 103-Pd (Theragenics model 200) seed in gold backing (no Silastic) was
reported. Chiu-Tsao et al. reported a dose decrease of about 10% for 125I (model
6711) seed with 20 mm gold plaque (no Silastic) at 7.6 mm. Since the emitted
photons from the 125I seed have higher energy than those emitted by 103-Pd seed,
more fluorescence photons are observed when 125I source is used. Due to the emis-
sion of fluorescence photons from the plaque backing for all seed and backing
models without any polymer insert, there is a small dose enhancement near the
plaque. The spectrum of fluorescence photons depends on the energy of photons
emitted by the seed and its active length and also depends on the composition of
plaque backing.
3.4 Effect of silastic insert
The central axis doses for the IR06-103Pd seeds in Silastic insert with plaque
backing are shown in Figure 8 relative to the doses for the same seeds in the water
medium. Silastic with an effective atomic number of10.7 has a greater attenuating
effect than water with an effective atomic number of Zeff (7.4) [17]. The average
variation in dose distribution due to Silastic insert relative to water is about 17%.
Thomson et al. [27] reported 17% dose reduction for Theragenics model 200103-Pd
seed at a distance of 1 cm in COMS plaque due to the presence of Silastic insert.
Chiu-Tsao et al. [16] calculated a 10% dose reduction at 1 cm for Silastic insert only,
in 20 mm COMS eye plaque for 125I, and 16% for 103-Pd (without gold backing)
relative to water along the central axis; according to their study also, they presented
that the effect of gold+ Silastic combination is comparable with the effect of Silastic
insert only. The reduction of dose for 125I source in Silastic insert is more than
103-Pd source due to its higher energy of emitted photons. The dose reduction for the
gold + Silastic combination relative to water medium as shown in Figures 6 and 8 is
Figure 5.
Comparison of the calculated anisotropy function of the IR06-103Pd seed versus other available sources
at 2 cm [18, 30].
12
Theory, Application, and Implementation of Monte Carlo Method in Science and Technology
Central axis depth (mm) a. Gold backing + Silastic
IR06-103Pd seeds
COMS eye plaque diameter (mm)
10 12 14 16 18 20 22
1 582.3 462.1 411.1 325.7 309.1 297.4 300.3
0.5 474.1 401.5 375.2 305.5 296.3 232.3 298.5
0 380.7 325.8 302.1 271.5 264.3 212.8 254.7
0.5 312.5 300.0 267.4 250.7 220.2 202.8 222.8
1 302.7 248.6 220.2 243.9 189.2 176.4 196.8
1.5 254.8 220.1 215.3 214.4 180.5 167.8 178.7
2 198.4 190.5 170.0 188.9 168.7 159.8 168.2
2.5 180.8 183.7 162.5 164.3 152.4 140.6 154.6
3 148.9 150.3 130.8 148.2 132.8 122.7 155.2
4 120.3 105.1 110.2 120.4 108.7 100.2 104.5
5 (Apex) 85.0 85.0 85.0 85.0 85.0 85.0 85.0
6 63.7 64.1 72.5 80.0 78.2 69.5 72.4
7 50.0 50.0 52.4 69.2 60.5 58.4 60.1
8 32.4 35.2 35.3 55.4 48.9 55.1 51.2
9 28.4 29.8 34.8 40.5 41.5 38 40.5
10 22.5 24.6 28.9 28.8 33.1 35.5 34.4
SK(U) 10.88 7.11 5.1 5.23 3.52 3.33 3.61
Central axis depth (mm) b. Gold backing + Silastic
103Pd model 200 seeds [14]
COMS eye plaque diameter (mm)
10 12 14 16 18 20 22
1 640.1 479.9 406.9 279.0 306.2 272.0 310.3
0.5 547.0 423.8 368.7 277.7 281.2 252.7 278.1
0 452.4 366.5 322.4 259.1 250.6 227.6 242.1
0.5 376.3 313.1 278.8 234.2 221.7 204.6 213.0
1 313.8 268.0 241.9 210.4 198.5 183.8 187.9
1.5 260.6 230.2 211.9 189.1 177.8 166.5 166.2
2 218.2 199.1 185.4 169.0 160.7 151.3 150.4
2.5 183.8 171.0 162.0 151.3 143.9 137.2 136.7
3 155.5 147.1 142.5 134.1 129.9 124.9 123.6
4 113.4 111.0 109.6 107.2 105.5 102.9 102.4
5 (Apex) 85.0 85.0 85.0 85.0 85.0 85.0 85.0
6 64.7 65.8 67.2 68.1 69.8 70.2 70.8
7 49.7 51.8 53.4 54.3 56.8 57.8 58.6
8 39.3 41.3 42.7 44.1 46.6 48.3 48.7
9 31.2 32.7 34.4 36.1 38.1 40.0 40.9
10 25.2 26.1 28.1 29.4 31.9 33.1 34.6
SK(U) 11.057 7.299 4.809 5.062 3.405 3.139 3.738
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about 19% at 1 cm and 17% and at 0.5 cm, and the average dose reduction due to the
presence of gold backing + Silastic insert along the COMS central axis loaded with
the new palladium seeds is about 18%. Thomson et al. have obtained a reduction of
the dose relative to water of 20% for 103-Pd seed at 1 cm in the COMS plaque central
axis; the main reduction is due to the Silastic insert. The comparison shows that the
dose reduction with IR06-103Pd seeds is lower along the central axis of the plaque
with the exception of sclera than the other two palladium seed models, Theragenics
200 and model 2335 loaded in COMS plaque.
3.5 Dose comparison at points of interest
To determine the effect of plaque backing and Silastic insert on dose rate at
points of interest, more Monte Carlo simulations were employed by replacing the
plaque backing and Silastic inserts with water. Table 5 presents the dose (in Gy) at
points of interest for different plaque materials of 20 and 16 mm COMS plaque fully
loaded with IR06-103Pd seeds. To obtain the dose at the points of interest in a water
Central axis depth (mm) c. Gold backing + Silastic/water medium
IR06-103Pd seeds
COMS eye plaque diameter (mm)
10 12 14 16 18 20 22
1 0.74 0.72 0.71 0.65 0.68 0.66 0.71
0.5 0.75 0.75 0.73 0.72 0.73 0.72 0.73
0 0.76 0.76 0.76 0.73 0.76 0.73 0.76
0.5 0.78 0.78 0.78 0.77 0.77 0.76 0.77
1 0.80 0.80 0.79 0.79 0.79 0.79 0.78
1.5 0.81 0.81 0.81 0.81 0.8 0.79 0.78
2 0.81 0.81 0.81 0.81 0.81 0.80 0.78
2.5 0.81 0.81 0.81 0.81 0.81 0.80 0.79
3 0.81 0.81 0.81 0.81 0.82 0.80 0.81
4 0.81 0.81 0.81 0.81 0.82 0.80 0.81
5 (Apex) 0.81 0.81 0.81 0.81 0.82 0.81 0.81
6 0.80 0.80 0.81 0.8 0.82 0.81 0.81
7 0.80 0.80 0.81 0.8 0.82 0.81 0.81
8 0.80 0.80 0.81 0.8 0.82 0.81 0.81
9 0.80 0.80 0.81 0.81 0.81 0.83 0.80
10 0.80 0.80 0.81 0.81 0.81 0.83 0.80
SK(U) 8.87 6.12 4 4.13 2.75 2.45 3.07
Table 4.
Central axis dose distributions: (a) in 10–22 mm diameter COMS eye plaques (gold backing + Silastic insert)
loaded with IR06-103Pd seeds, (b) gold backing + Silastic insert loaded with 103Pd model 200 seeds [14]
and (c) the ratio of the central axis dose of the 10–22 mm COMS plaque (gold backing + silastic) to the central
axis dose in water medium loaded with IR06-103Pd seeds.
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medium, the air kerma strength for each seed, (SK), is required to deliver 85 Gy to
the tumour apex in 168 hours. All of the results have been renormalized to deliver
the same dose (85 Gy) to the apex of the tumour. The results are compared with the
dose at the same points when COMS plaque is loaded with Theragenics model 200
and 6711-125I seeds. According to Table 5, dose decreases at the optic disk by40%
when moving a plaque from nasal to temporal equatorial centers. This is due to the
fact that the optic disk is not centered on the eye anterior-posterior (AP) axis and is
nearer the nasal plaque. For the plaque position between the posterior pole and
equator temporal to the eyeball, the decrease in dose is due to the gold backing, and
Silastic insert related to water medium is about 14% for IR06-103Pd seed and 21%
for the model 200 at the opposite side of the eye [17]. When compared to identical
plaques loaded with model 6711 125I sources, the doses at points of interest are
consistently lower in plaque loaded with any of the 103-Pd models in this study.
Figure 7.
Ratio of the doses along the plaque’s central axis for 20 mm COMS plaque (no Silastic insert) loaded with
IR06-103Pd, model 200 and model 2335 seeds to the doses in water medium.
Figure 6.
Ratio of the doses along the plaque’s central axis for 20 mm COMS plaque fully loaded with IR06-103Pd to the
doses in water medium.
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Figure 8.
Ratio of the doses along the plaque’s central axis for 20 mm COMS plaque (gold backing + Silastic insert) fully
loaded with IR06-103Pd, model 200 and model 2335 seeds [17] to the doses in water medium.










Centre of eye 29.08 34.31 30.82 34.37
Macula (equator and p.p) 15.57 17.22 16.55 18.29
Optic disk (temporal) 7.52 8.81 7.98 8.85
Optic disk (nasal) 18.29 21.47 19.42 21.44
Centre of lens (equator and
p.p)
16.21 18.98 17.23 19.00
Sclera 351.81 367.38 374.68 383.73
Apex 85.00 85.00 85.00 85.00
Lacrimal gland (nasal) 4.82 5.59 5.12 5.62
Opposite side 3.39 3.94 3.59 3.95
b. 16 mm COMS
Water medium Gold backing + Silastic
IR06-103Pda Theragenics 200b IR06-103Pda Theragenics 200b 6711-125Ic
Centre of eye 22.52 22.75 17.8 18.3 23.79
Macula (equator and p.p) 10.61 11.43 9.8 8.089 12.82
Optic disk (temporal) 6.32 7.193 5.12 5.35 8.98
Optic disk (nasal) 19.63 21.65 13.67 14.13 21.02
Centre of lens (equator and
p.p)
15.63 16.34 11.83 12.5 17.58
Sclera 297.41 287.92 261.4 211 222.9
Apex 85.00 85.00 68.23 68.7 74.43
Lacrimal gland (nasal) 3.72 — 2.75 3.03 —





Doses in grey at points of interest for (a) 20 mm (b) 16 mm COMS eye plaque loaded with IR06-103Pd seeds
compared with the doses at the same points for model 200 (103Pd) and model 6711 (125I), in 16 mm
COMS eye plaque. Eye plaque centerd in the midway of equator and posterior pole (equator and p.p) and
centerd on equator temporal and nasal.
16
Theory, Application, and Implementation of Monte Carlo Method in Science and Technology
4. Conclusion
In this study, the dosimetry of a new design brachytherapy seed IR06-103Pd was
determined by Monte Carlo using MCNP (version 5). Simulations were considered
in three seed orientations with the result that there are no significant statistical
differences among the orientations (i.e., ideal, vertical and diagonal). The dosimet-
ric parameters of the new seed are presented in TG-43U1 format. These parameters
are in acceptable agreement with those of other commercially available seed
models. Thus, the IR06-103Pd seed is dosimetrically suitable for use in routine
brachytherapy where the other similar seeds are employed. Also in this study, the
dosimetry of IR06-103Pd seed was evaluated in COMS eye plaques and compared to
results for commercially available 103-Pd and 125I seeds in the same plaque
geometries.
The COMS Silastic insert has a significant effect in reducing dose along the
plaque central axis. The presence of gold backing enhances the dose near the plaque
gold surfaces. This effect is due to secondary fluorescence photons arising from the
backing material. Due to the energy of these emissions, the effect is significantly
attenuated at a distance >2 mm. The dose decrease depends on the composition of
the plaque backing material and therefore on the emitted photon spectrum of the
seeds and the fluorescence of the backing material.
The combination of gold backing with the Silastic insert decreases the dose
relative to water by 19% at 1 cm along the plaque central axis.
This study shows that this 19% effect is lower than for either model 200 or 2335
103-Pd seeds. Doses to interest points including the macula, optic disk, lens, sclera
and lacrimal gland have been determined; and also the effects of plaque backing
material and Silastic insert have also been studied at these points. The study affirms
that dose and dose rate at these points of interest in COMS plaques are routinely
lower when using 103-Pd rather than 125-I seeds. The dose to the proximal sclera,
underlying the plaque, is greater using 103-Pd seeds due to lessened penetration than
125-I seeds.
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